High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

Bibliographic Details
Main Authors:	Jahanzaib Khwaja, Joshua Bomsztyk, Shameem Mahmood, Brendan Wisniowski, Raakhee Shah, Anish Tailor, Kwee Yong, Rakesh Popat, Neil Rabin, Charalampia Kyriakou, Jonathan Sive, Simona Degli Esposti, Daniel F. P. Larkin, Sarah Worthington, Alyse Hart, Emma Dowling, Nuno Correia, Ceri Bygrave, Andrzej Rydzewski, Krzysztof Jamroziak, Ashutosh D. Wechalekar
Format:	Article
Language:	English
Published:	Nature Publishing Group 2022-09-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-022-00717-2

Similar Items

P918: HIGH RESPONSES RATES WITH SINGLE AGENT BELANTAMAB MAFODOTIN IN RELAPSED SYSTEMIC AL AMYLOIDOSIS
by: J. Khwaja, et al.
Published: (2022-06-01)

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
by: Sagar Lonial, et al.
Published: (2021-05-01)

Corneal epithelial changes in a patient treated with belantamab mafodotin
by: Leandro Inferrera, et al.
Published: (2023-01-01)

The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
by: Melody R. Becnel, et al.
Published: (2020-12-01)

Isatuximab and Belantamab Mafodotin: A Primer to an Evolving Multiple Myeloma Landscape
by: Rebecca Gonzalez, et al.
Published: (2021-04-01)

Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
by: Sonia Morè, et al.
Published: (2023-05-01)

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
by: Offidani M, et al.
Published: (2021-06-01)

Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study
by: Anna Cardellino, et al.
Published: (2023-12-01)

Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
by: Asim V. Farooq, et al.
Published: (2020-09-01)

P44 DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN
by: U. Munawar, et al.
Published: (2023-05-01)

P20: POLYCENTRIC “REAL LIFE” STUDY OF BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: R Iula, et al.
Published: (2022-04-01)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-07-01)

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
by: Neupane K, et al.
Published: (2021-07-01)

Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
by: Grace Lassiter, et al.
Published: (2021-01-01)

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
by: Chetan Rathi, et al.
Published: (2021-08-01)

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL
by: A. Nooka, et al.
Published: (2023-05-01)

S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
by: Efstathios Kastritis, et al.
Published: (2023-08-01)

PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE
by: Malin Hultcrantz, et al.
Published: (2023-08-01)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-08-01)

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
by: Javier de la Rubia, et al.
Published: (2023-05-01)

Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
by: Jon Collins, et al.
Published: (2023-10-01)

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience
by: Rossella Iula, et al.
Published: (2022-11-01)

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
by: Shah A, et al.
Published: (2021-09-01)

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
by: Joseph NS, et al.
Published: (2021-08-01)

P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
by: E. Kastritis, et al.
Published: (2022-06-01)

P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
by: R Popat, et al.
Published: (2022-04-01)

PB2158: RELAPSING/REFRACTORY ABDOMINAL WALL EXTRA-MEDULLARY PLASMACYTOMAS DEMONSTRATING A RAPID COMPLETE RESPONSE TO BELANTAMAB MAFODOTIN
by: Mohamed Ali, et al.
Published: (2023-08-01)

P33 EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL-LIFE SETTING: THE ALFA STUDY
by: M. Roussel, et al.
Published: (2023-05-01)

Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging
by: Rita Mencucci, et al.
Published: (2022-05-01)

Semi-automation of keratopathy visual acuity grading of corneal events in belantamab mafodotin clinical trials: clinical decision support software
by: Mala K. Talekar, et al.
Published: (2023-10-01)

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY
by: A. Suvannasankha, et al.
Published: (2022-06-01)

Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm)
by: A. Medaglia, et al.
Published: (2020-09-01)

Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report
by: Kevin Marquant, et al.
Published: (2021-10-01)

P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-6 ARM-A INTERIM ANALYSIS
by: H. Quach, et al.
Published: (2022-06-01)

P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Ajai Chari, et al.
Published: (2023-08-01)

Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
by: Adrián Alegre, et al.
Published: (2022-12-01)

Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up
by: A. Medaglia, et al.
Published: (2020-09-01)

P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
by: S. Z. Usmani, et al.
Published: (2022-06-01)

P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
by: S Usmani, et al.
Published: (2022-04-01)

P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9
by: Saad Z Usmani, et al.
Published: (2023-08-01)